[Hypolipidemic therapy in patients with non-alcoholic fatty liver disease].
To date generally accepted that one of the major risk factors for cardiovascular disease (CVD) and atherosclerosis is dyslipidemia. The undoubted fact is that the liver plays an important role in the development of atherogenic dyslipidemia, and simultaneously being the target organs, which leads to the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is a major risk factor for CVD, it limits the possibilities for adequate lipid-lowering therapy, increasing cardiovascular risk. In this regard, the treatment of atherogenic dyslipidemia with statins and fibrates appropriate to hepatoprotectors disposal. Hepatoprotectors choice depends on the stage of NAFLD. At the steatosis stage of the NAFLD expedient method of statins in combination with essential phospholipids. At the nonalcoholic steatohepatitis (NASH) stage of NAFLD patient should receive statin therapy combined with ursodeoxycholic acid (UDCA). Patients with high levels of hypercholesterolemia in achieving target levels of cholesterol--low lipoprotein density (LDL-cholesterol) and decrease the side effects is the best combination of statins with the cholesterol absorption inhibitor. The complex lipid-lowering therapy in patients with NAFLD should include drugs that normalize the intestinal microflora (intestinal antiseptic, pre- and probiotics).